NCT Number: NCT00093171
Study Evaluating rFIX; BeneFIX® in Hemophilia B
The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Los Angeles, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Hemophilia B (FIX:C less than 2%)
- Previous treatment of at least 150 exposure days using any FIX product
- 12 years of age and older
Exclusion criteria
- The patient has a currently detectable factor IX inhibitor or a history of inhibitors. (A family history of inhibitors will not exclude the patient)
- Known hypersensitivity to protein pharmaceuticals or agents related to the test article, e.g. hamster proteins
- Patient has a genetic coagulation disorder other than hemophilia B
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
An Open-label Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Previously Treated Patients (PTPs) With Hemophilia B (FIX:C ≤2%)
Important dates
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Oct 7, 2004
- Registry last updated
- Aug 21, 2009
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B
NCT03307980
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sacramento, California, United States
View Trial DetailsRecombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy
NCT06399289
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, Beijing Municipality, China
View Trial DetailsStudy of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
NCT05360706
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Berlin, Germany
View Trial DetailsDose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
NCT00979238
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Stanford, California, United States
View Trial Details